With multiple approved products,the field of gene therapies has gained substantial momentum over the lastcouple of decades; innovator companies are gradually progressing theirproprietary therapy candidates with cautious optimism
Roots Analysis is pleased to announce the publication of its recent study,titled, “Gene Therapy Market(3rd Edition), 2019-2030”.
The report features an extensive study of the currentmarket landscape of gene therapies,primarily focusing on gene augmentation-based therapies, oncolytic viraltherapies and genome editing therapies. The study also features an elaboratediscussion on the future potential of this evolving market. In addition toother elements, the study includes:
§ Adetailed review of the overall landscape of gene therapies and genome editingtherapies.
§ Adiscussion on the various types of viral and non-viral vectors.
§ Aworld map representation, depicting the most active geographies, and a bull’seye analysis, highlighting the distribution of clinical-stage pipelinecandidates by phase of development, type of vector and type of therapy.
§ Adiscussion on the regulatory landscape related to gene therapies across variousgeographies.
§ Detailedprofiles of marketed and phase II/III and gene therapies.
§ Anelaborate discussion on the various commercialization strategies that can beadopted by drug developers for use across different stages of therapy development.
§ Areview of various emerging technologies and therapy development platforms thatare being used to design and manufacture gene therapies.
§ Anin-depth analysis of the various patents that have been filed / granted relatedto gene therapies and genome editing therapies, since 2016.
§ Ananalysis of the various mergers and acquisitions that have taken place in thisdomain, highlighting the trend in the number of companies acquired between2014-2019.
§ Ananalysis of the investments made at various stages of development in companiesthat are focused in this area, between 2014-2019.
§ Ananalysis of the big biopharma players engaged in this domain.
§ Acase study on the prevalent and emerging trends related to vectormanufacturing, with information on companies offering contract services formanufacturing vectors.
§ Adiscussion on the various operating models adopted by gene therapy developersfor supply chain management.
§ Ananalysis of the various factors that are likely to influence the pricing ofgene-based therapies.
§ Adetailed market forecast, featuring analysis of the current and projectedfuture opportunity across key market segments (listed below)
ToRequest for sample report - https://www.rootsanalysis.com/reports/268/request-sample.html
§ Keytherapeutic areas
§ Autoimmunedisorders
§ Cardiovasculardiseases
§ Geneticdisorders
§ Hematologicaldisorders
§ Metabolicdisorders
§ Ophthalmicdisorders
§ Oncologicaldisorders
§ Others
§ Type of vector
§ Adeno associated virus
§ Adenovirus
§ Herpes simplex virus type 1
§ Lentivirus
§ Plasmid DNA
§ Retrovirus
§ Vaccinia Virus
§ Typeof therapy
§ Exvivo
§ Invivo
§ Typeof gene modification
§ Gene augmentation
§ Immunotherapy
§ Oncolytic therapy
§ Others
§ Routeof administration
§ Intraarticular
§ Intracerebellar
§ Intramuscular
§ Intradermal
§ Intravenous
§ Intravitreal
§ Intravesical
§ Subretinal
§ Others
§ Keygeographical regions
§ NorthAmerica
§ Europe
§ Asia-Pacific
§ Transcriptsof interviews held with the following senior level representatives ofstakeholder companies
§ AdamRogers (CEO, Hemera Biosciences)
§ AlHawkins (CEO, Milo Biotechnology)
§ BuelDan Rodgers (Founder & CEO, AAVogen)
§ CedricSzpirer (Executive & Scientific Director, Delphi Genetics)
§ ChristopherReinhard (CEO and Chairman, Cardium Therapeutics)
§ RyoKubota (Chairman, President and Chief Executive Officer, Acucela)
§ JeffreyHung (CCO, Vigene Biosciences)
§ MarcoSchmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory)
§ MichaelTriplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics)
§ RobertJan Lamers (CEO, Arthrogen)
§ TomWilton (Chief Business Officer, LogicBio Therapeutics)
Key companies coveredin the report
§ Advantagene
§ Advaxis
§ BioMarin
§ bluebirdbio
§ FKDTherapies
§ FreelineTherapeutics
§ GenSightBiologics
§ Gradalis
§ InovioPharmaceuticals
§ MarsalaBiotech
§ OrchardTherapeutics
§ Pfizer
§ SareptaTherapeutics
§ SparkTherapeutics
§ Tocagen
§ Transgene
§ uniQureBiopharma
§ VBLTherapeutics
§ ViroMed
For more informationplease click on the following link:
Other RecentOfferings
1. Viral Vectors,Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition),2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA andOther Vectors)
2. CAR-T Therapies Market (2nd Edition), 2019-2030
3. Global T-Cell (CAR-T,TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
